The Latest Cardiac and Vascular News
Recardio Inc., a clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the positive study results of Recardio’s Phase 2 clinical study in Acute Myocardial Infarction were presented on Saturday, May 21, 2022, during the Latebreaker Session at the World Congress on Acute Heart Failure 2022 in […]
The study met its primary endpoint of improved systolic blood pressure (SBP) profile at 6 hours with the istaroxime group performing significantly better than the control group Increased SBP also persisted through 24 hours The study also met several key secondary endpoints associated with improving cardiac function Investor conference call […]
Ad hoc announcement pursuant to Art. 53 LR Aprocitentan reduces blood pressure compared to placebo by week 4 of treatment, the effect is maintained and confirmed over a period of 48 weeks, and is generally well tolerated with no major safety concerns Primary and key secondary endpoints were met with […]
Investigators Report Positive Findings From Feasibility Study of CCM in Heart Failure With Preserved Ejection Fraction at the European Society of Cardiology Heart Failure 2022 Congress MADRID and MARLTON, N.J., May 23, 2022 (GLOBE NEWSWIRE) — Impulse Dynamics, a global medical device company dedicated to improving the lives of people […]
– New Exploratory Findings from 18-Month Analysis of HELIOS-A Suggest that Treatment with Investigational Vutrisiran May Benefit Patients with Hereditary ATTR (hATTR) Amyloidosis and Cardiac Involvement – Improvements in NT-proBNP and Echocardiographic Parameters Seen in Cardiac Subpopulation – Reductions in Technetium Uptake Observed in Patients with High Grade Uptake at […]
Latest data from the SANTORINI disease registry show that the cardiovascular (CV) risk of hypercholesterolaemia patients was underestimated considerably in the clinical setting.1,2,3 SANTORINI data show that nearly 80% of patients who are at high-risk or very high-risk of CV events do not attain guideline recommended low-density lipoprotein cholesterol (LDL-C) […]
TNX-201 (oral imatinib modified release tablets) Formulation Development has been Successfully Completed Manufacturing Underway to Support Phase 3 PAH Study (IMPROVE) MORRISVILLE, N.C.–(BUSINESS WIRE)–Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, […]
First clinical data of implantable heart sensor with remote measurement capabilities presented at prestigious Late-Breaking Science forum at the ESC Heart Failure 2022 TEL AVIV, Israel–(BUSINESS WIRE)–Vectorious Medical Technologies Ltd., an innovator in implantable hemodynamic monitoring in heart failure (HF), today announced results of VECTOR-HF I, a first-in-man clinical study […]
– Lead Clinical Candidate, JK07, Demonstrates Favorable Safety and Further Promising Activity in Cohort 2 of Phase 1b Heart Failure with Reduced Ejection Fraction Study; Enrollment in Cohort 3 Now Ongoing – – Clinical Trial Application Submitted in Europe for Lead Oncology Program JK08, the first CTLA-4/IL-15 Antibody Fusion Protein, […]
EPLive 2022 is a two-day conference that draws the world’s top cardiac electrophysiology experts AUSTIN, Texas, May 20, 2022 /PRNewswire/ — On June 2 and 3, 2022, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center will host its sixth international symposium on complex arrhythmias, EPLive 2022. EPLive is an intensive, two-day […]
